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Background
• 8% of disease burden from hypertension (HT)1
• Numerous gaps between evidence and treatment2
– “Rule of halves”, and more
• Evidence strongly supports effectiveness of pharmacist 
input in reducing blood pressure3
– “Controlling Hypertension through Innovations in Primary 
Care” (CHIP C)
1. Australian Institute of Health and Welfare. Australia's Health 2008. Canberra. , 2008.
2. National Institute of Clinical Studies. Evidence-Practice Gaps Report Volume 2. Achieving optimal 
control of blood pressure. Melbourne: NICS 2005:34-35.
3. Fahey T, Schroeder K, Ebrahim S, Glynn L. Interventions used to improve control of blood pressure in 
patients with hypertension (Review). Cochrane Database of Systematic Reviews, 2006.
Aim
• To examine the sustainability of community pharmacist 
involvement in a quality improvement program aimed 
at increased delivery of evidence-based HT 
interventions during routine primary care
Study design
• Recruitment via direct approach and advertisement
– Individual participants
• Randomisation by pharmacy to one of three groups
– Stratified according to adjusted baseline interventions
– Preceded by baseline audit and patient survey
• Minimum participation requested:
– Distribution of baseline and follow up patient surveys 
– Audit of HT interventions for consenting GPs
• Primary outcome: level of engagement in self-audit 
– Contact participants ~every 4-6 weeks
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Recruitment of pharmacists
• 55 pharmacists from 30 pharmacies at baseline
– Four extra pharmacists commenced pre-randomisation
– Generally enthusiastic response for recruitment
• 47 approving GP’s, 15 seeking ongoing information
– Written approval not practical
– Locum GP’s only in rural area
• 5 pharmacies withdrew prior to randomisation (May 2009)
– Pharmacy refit (1)
– Staff changes/departures (3)
– Unable to contact GP for approval (1)
• Delayed roll-out in places, February audit disregarded
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Discussion
• Remunerated activities (must?) take precedence
– Plenty of goodwill/intention, but not resources
– Multiple competitors for free pharmacist time
– Cyclical pharmacy research funding has negative effect
• New systems required for sustainable implementation
– Absence of necessary infrastructure and systems
– Questions current cpd approaches
• Staff turnover to increase with chain pharmacies?
– Loss of ‘champions’
